Executive Committee

Dr. Peggi Angel, President

Peggi Angel is currently Assistant Professor at Medical University of South Carolina, where she works on technology advancements in MALDI IMS and application to cardiovascular disease and cancer. Peggi attended graduate school at the University of Georgia’s Complex Carbohydrate Research Center, graduating with a PhD in 2007. Her graduate research was on quantitative proteomics and N-linked glycoproteomics in mammalian development. After a postdoctoral study at Emory University focused on membrane proteomics of fetal alcohol syndrome, she won a competitive Postdoctoral Fellowship with the Systems-based Consortium for Organ Design and Engineering. With the Fellowship, she worked at Vanderbilt University on methods using MALDI IMS for developmental biology and participated in establishing the National Research Resource in Imaging Mass Spectrometry. Peggi has developed IMS methods for increasing sensitivity of protein detection from tissues, analysis and identification of lipids in negative mode at high spatial resolution, metabolomics on tissue and cell culture, targeted protein detection in tissues, proteomics of thin tissue sections, and on-tissue chemistries. 

Dr. Christopher R. Anderton, President-Elect

Chris Anderton is currently a staff scientist at the Environmental Molecular Sciences Laboratory (EMSL), which is located on the Pacific Northwest National Laboratory (PNNL) campus. Chris received his BS in chemistry at the University of Colorado at Colorado Springs in 2005. He attained his PhD in chemistry at the University of Illinois at Urbana–Champaign in 2011, under Mary L. Kraft, where his graduate work focused on using secondary ion mass spectrometry (ToF-SIMS and NanoSIMS) in conjunction with atomic force microscopy and scanning electron microscopy for multi-technique correlative analysis of supported lipid membranes. Afterward, he received a US National Research Council Postdoctoral Associateship to work at the National Institute of Standards and Technology under Anne L. Plant, where he studied how eukaryotic cells respond to changes in the physicochemical properties of their extracellular environment, using force microscopy, fluorescence microscopy, and ToF-SIMS. In 2013, he joined the Mass Spectrometry Group at EMSL, where he is now leading the effort in developing new imaging mass spectrometry instrumentation and capabilities to elucidate chemical interactions occurring within microbial communities, soils, and the rhizosphere. In his free time, Chris loves to travel and explore the great outdoors.

Dr. Richard R. Drake, Past-President

Dr. Drake is a Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina and SmartState Endowed Chair in Proteomics. He is an experienced protein biochemist and glycobiologist, with particular expertise in imaging MS of tumor tissues and biomarker discovery from clinical fluids. Dr. Drake received a B.S. from Centre College, Danville, KY, and a Ph.D. from the University of Kentucky, both in Biochemistry and Molecular Biology. Post-doctoral training in glycobiology was done with Alan Elbein at the University of Texas Health Science Center at San Antonio. Current efforts are in the large scale application of N-glycan MS imaging methods developed in his laboratory to prostate, pancreas, liver, and breast tumors. The goal is to develop glycan biomarkers associated with tumor, stroma and immune regions of tumors, in two and three dimensions.